GEN Exclusives

A Conversation with J. Craig Venter, Ph.D.

The biotech pioneer and entrepreneur speaks on digitizing life and bioteleportation.

Dr. Venter is founder, chairman, and CEO of the J. Craig Venter Institute, and founder and CEO of Synthetic Genomics, La Jolla, CA.

(Page
1
of
1)

INDUSTRIAL BIOTECHNOLOGY: Dr. Venter, in the short time that has elapsed since you created the first synthetic genome and new organism, what are the main things this discovery has taught us?

CRAIG VENTER: It has taught and proved that life is a DNA software system and that the information contained within that DNA code contains all the information necessary for life.

IB: Did anything in particular about the process or the findings surprise you?

CRAIG VENTER: The fact that the process works by being able to transplant genomes gave us a lot of clues concerning how evolution occurred, which is actually quite different than what people had thought. The prevailing theories being that just a lot of point mutations collected over billions of years. The fact that we can actually find evidence in the environment for entire genomes being transferred at one time–such as chloroplasts and mitochondria–suggests that evolution is more punctate than a lot of people think, adding perhaps thousands of changes in one event instead of just a selection of minor changes.

IB: What do you see as the main R&D challenges for synthetic biology within the industrial biotechnology community?

CRAIG VENTER: The work to create a new life form was a pilot, proof-of-principle study to show that we could take digital information into a computer, make the chemical version of that information in DNA, boot up that synthetic DNA, and make cells that are driven by the synthetic DNA. In practice, to affect the future of biotechnology and industrial biotechnology we will have to apply those tools in a comprehensive fashion to solve some of the biggest problems out there. At Synthetic Genomics that is what we're doing. We are working on engineered cells to produce new sources of food and chemicals, and potentially fuel in the long run. We are working on new ways to manufacture vaccines and make antimicrobials. This technology will affect everything in industrial biotechnology; it's just a matter of how fast that happens. I argue in my book, Life at the Speed of Light, that this could be the start of a new Industrial Revolution.

Industrial Biotechnology, published by Mary Ann Liebert, Inc., is a peer-reviewed bimonthly research journal focused on biobased industrial and environmental products and processes. The above article was first published in Industrial Biotechnology online ahead of print in January of 2014 with the title “A Conversation with J. Craig Venter, Ph.D.”. The views expressed here are those of the authors and are not necessarily those of Industrial Biotechnology journal, Mary Ann Liebert, Inc., publishers, or their affiliates. No endorsement of any entity or technology is implied.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Be sure to take the GEN Poll

Climate Change

How would you describe the researchers response to the 2°C global temperature target?

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

41.2%

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

23.5%

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.